# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-26-032159
**Filing Date:** 2026-3
**Character Count:** 24634
**Document Hash:** 34a689d3aef06854fb71418703e0f3cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-032159.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001104659-26-032159

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**EFFECTIVENESS DATE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294458
- **FILM NUMBER:** 26775082

**BUSINESS ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 972-4-770-6377

**MAIL ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

**As filed with the Securities and Exchange Commission on March 19, 2026**

Registration No. 333-

**United States**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware 45-2973162 <br> (State or other jurisdiction of <br> incorporation or organization) (I.R.S. Employer Identification No.)

322 W 57th St, #33B

New York, New York 10019

(Address of Principal Executive Offices)

DarioHealth Corp. 2020 Equity Incentive Plan

(Full title of the plan)

Mr. Erez Raphael

Chief Executive Officer

322 W 57th St, #33B

New York, New York 10019

Telephone: 972-4-770-6377

(Name, Address and Telephone Number of Agent For Service)

**Copies to**:

Oded Har-Even, Esq.

Ron Ben-Bassat, Esq.

Sullivan & Worcester LLP

1251 Avenue of the Americas

New York, NY 10020

Telephone: (212) 660-3000

Facsimile: (212) 660-3001

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act

Large accelerated filer ◻ Accelerated filer ◻ Non-accelerated filer ⌧ Smaller reporting company ⌧ Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

On October 14, 2020, DarioHealth Corp. (the "Company") filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465920114901/0001104659-20-114901-index.htm) (File No. 333-249474) (the "Original Registration Statement") with the Securities and Exchange Commission (the "Commission") to register an aggregate of 45,000 shares of the Company's common stock, $0.0001 par value per share (the "Common Stock"), that may be issued pursuant to the Company's 2020 Equity Incentive Plan, as amended (the "2020 Plan").

On January 8, 2021, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465921002464/0001104659-21-002464-index.htm) (File No. 333-251968) (the "Second Registration Statement") with the Commission to register an additional 46,445 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On June 8, 2021, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465921078232/0001104659-21-078232-index.htm) (File No. 333-256897) (the "Third Registration Statement") with the Commission to register an additional 35,000 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On January 7, 2022, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465922002295/0001104659-22-002295-index.htm) (File No. 333-262056) (the "Fourth Registration Statement") with the Commission to register an additional 66,982 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On January 6, 2023, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465923001860/0001104659-23-001860-index.htm) (File No. 333-269147) (the "Fifth Registration Statement") with the Commission to register an additional 99,718 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On January 19, 2024, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465924005220/tm243569d1_s8.htm) (File No. 333-276617) (the "Sixth Registration Statement") with the Commission to register an additional 124,689 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On July 5, 2024, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465924078091/0001104659-24-078091-index.htm) (File No. 333-280706) (the "Seventh Registration Statement") with the Commission to register an additional 150,000 shares of Common Stock that may be issued pursuant to the 2020 Plan.

Pursuant to the 2020 Plan, the number of shares of Common Stock of the Company made available under the 2020 Plan for each of the calendar years ending December 31, 2024, and December 31, 2025 shall be increased by an additional number of shares of Common Stock equal to six percent (6%) of the number of shares of Common Stock issued and outstanding on a fully diluted basis (as defined in the 2020 Plan) on the immediately preceding December 31.

On January 17, 2025, the Company filed a Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1533998/000110465925004498/0001104659-25-004498-index.htm) (File No. 333-284346) (the "Eighth Registration Statement" and together with the Original Registration Statement, the Second Registration Statement, the Third Registration Statement, the Fourth Registration Statement, the Fifth Registration Statement, the Sixth Registration Statement and the Seventh Registration Statement, the "Prior Registration Statements") with the Commission to register an additional 327,052 shares of Common Stock that may be issued pursuant to the 2020 Plan.

On July 23, 2025 the Company's stockholders voted to amend and restate the Company's 2020 Plan, to (i) provide that for each of the calendar years ending on December 31, 2026, December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, the number of shares available under the 2020 Plan shall be increased by an additional number of shares of the Company's Common Stock, equal to six percent (6%) of the number of shares of Common Stock issued and outstanding on a fully diluted basis on the immediately preceding December 31; and (ii) authorize the grant of restricted stock units as a permissible form of award under the 2020 Plan.

On January 29, 2026, following the approval by the Company's stockholders at the Company's 2026 Annual Meeting of Stockholders, the number of shares issuable pursuant to the 2020 Plan was increased by an additional 500,000 shares of Common Stock.

The Company is filing this registration statement to register an additional 1,135,000 shares of Common Stock that may be issued under the 2020 Plan.

Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference, except for Item 3 and Item 8 of Part II of the Prior Registration Statements, which are being updated by this registration statement.

*All information included herein relating to shares or price per share reflects the 20-for-1 reverse stock split effected by the Company on August 28, 2025.*

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The documents containing the information required in Part I of this registration statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act") in accordance with the rules and regulations of the Commission. Such documents are not being filed with the Commission either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference.**

The following documents, which have been filed by the Company with the Commission are incorporated by reference in and made a part of this registration statement, as of their respective dates:

(1) Our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Commission on [March 19, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1533998/000110465926031621/drio-20251231x10k.htm) ;

(2) Our Current Reports on Form 8-K, as filed with the Commission on [January 29, 2026](https://www.sec.gov/Archives/edgar/data/1533998/000110465926007974/0001104659-26-007974-index.htm) and [February 2, 2026](https://www.sec.gov/Archives/edgar/data/1533998/000110465926009247/0001104659-26-009247-index.htm) ; and

(3) The description of our Common Stock contained in [our Registration Statement on Form 8-A filed with the Commission on February 25, 2016](http://www.sec.gov/Archives/edgar/data/1533998/000114420416084331/v432688_8-a12b.htm) , including any amendments and reports filed for the purpose of updating such description.

All documents subsequently filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| [4.1](https://www.sec.gov/Archives/edgar/data/1533998/000110465926009247/tm264836d1_ex3-1.htm) | [Amended and Restated Certificate of Incorporation as amended on February 2, 2026 (incorporated by reference to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 2, 2026).](https://www.sec.gov/Archives/edgar/data/1533998/000110465926009247/tm264836d1_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1533998/000110465924049443/tm2412279d1_ex3-1.htm) | [Amended and Restated Bylaws (incorporated by reference to the Company's Current Report on Form 8-K filed with the Commission on April 19, 2024).](https://www.sec.gov/Archives/edgar/data/1533998/000110465924049443/tm2412279d1_ex3-1.htm) |
| [5.1\*](tm268351d1_ex5-1.htm) | [Opinion of Sullivan & Worcester LLP.](tm268351d1_ex5-1.htm) |
| [23.1\*](tm268351d1_ex23-1.htm) | [Consent of Kost Forer Gabbay & Kasierer, A Member of Ernst & Young Global.](tm268351d1_ex23-1.htm) |
| [23.2\*](tm268351d1_ex23-2.htm) | [Consent of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited.](tm268351d1_ex23-2.htm) |
| [23.3\*](tm268351d1_ex5-1.htm) | [Consent of Sullivan & Worcester LLP (contained in Exhibit 5.1).](tm268351d1_ex5-1.htm) |
| [24.1\*](#sig_001) | [Power of Attorney (included on signature page).](#sig_001) |
| [99.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/1533998/000110465925054861/tm2515450d4_def14a.htm) | [The registrant's Amended and Restated 2020 Equity Incentive Plan (Incorporated by reference to Annex A to the registrant's Proxy Statement on Schedule 14A filed with the Commission on May 30, 2025).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1533998/000110465925054861/tm2515450d4_def14a.htm) |
| [99.2](https://www.sec.gov/ix?doc=/Archives/edgar/data/1533998/000110465925123724/tm2533158-3_def14a.htm) | [The registrant's amendment to the Amended and Restated 2020 Equity Incentive Plan (Incorporated by reference to Annex A to the registrant's Proxy Statement on Schedule 14A filed with the Commission on December 12, 2025).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1533998/000110465925123724/tm2533158-3_def14a.htm) |
| [107\*](tm268351d1_ex-filingfees.htm) | [Filing Fee Table.](tm268351d1_ex-filingfees.htm) |

---

\* filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, New York, on the 19th day of March, 2026.

---

| | |
|:---|:---|
| **DARIOHEALTH CORP.** | **DARIOHEALTH CORP.** |
| By: | /s/ Erez Raphael |
|  | Name: Erez Raphael |
|  | Title: Chief Executive Officer |

---

**power of attorney and signatures**

We, the undersigned officers and directors of DarioHealth Corp., hereby severally constitute and appoint Erez Raphael and Chen Franco-Yehuda, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Person** | **Capacity** | **Date** |
| /s/ Erez Raphael | Chief Executive Officer and Director | March 19, 2026 |
| Erez Raphael | (Principal Executive Officer) |  |
| /s/ Chen Franco-Yehuda | Chief Financial Officer, Secretary and Treasurer | March 19, 2026 |
| Chen Franco-Yehuda | (Principal Financial and Accounting Officer) |  |
| /s/ Yoav Shaked | Chairman of the Board of Directors | March 19, 2026 |
| Yoav Shaked |  |  |
| /s/ Lawrence Leisure | Director | March 19, 2026 |
| Lawrence Leisure |  |  |
| /s/ Hila Karah | Director | March 19, 2026 |
| Hila Karah |  |  |
| /s/ Dennis Matheis | Director | March 19, 2026 |
| Dennis Matheis |  |  |
| /s/ Dennis M. McGrath | Director | March 19, 2026 |
| Dennis M. McGrath |  |  |
| /s/ Adam K. Stern | Director | March 19, 2026 |
| Adam K. Stern |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm268351d1_ex5-1img01.jpg)

March 19, 2026

DarioHealth Corp.

322 W 57th St, #33B

New York, New York 10019

Re: <u>DarioHealth Corp. Registration Statement on Form S-8</u>

Ladies and Gentlemen:

In connection with the registration under the Securities Act of 1933, as amended (the "<u>Act</u>"), by DarioHealth Corp., a Delaware corporation (the "<u>Company</u>"), of 1,135,000 shares of its common stock, par value $0.0001 per share (the "<u>Registered Shares</u>"), that are to be offered and may be issued under the DarioHealth Corp. Amended and Restated 2020 Equity Incentive Plan (the "<u>Plan</u>"), the following opinion is furnished to you to be filed with the Securities and Exchange Commission (the "<u>Commission</u>") as Exhibit 5.1 to the Company's Registration Statement on Form S-8 (the "<u>Registration Statement</u>") under the Act.

We have acted as counsel to the Company in connection with the Registration Statement, and we have examined originals or copies, certified or otherwise identified to our satisfaction, of the Registration Statement, the Certificate of Incorporation of the Company as presently in effect, the bylaws, minute books and corporate records of the Company, and such other documents as we have considered necessary in order to furnish the opinion hereinafter set forth.

We express no opinion herein as to any laws other than the General Corporation Law statute of the State of Delaware, and we express no opinion as to state securities or blue sky laws.

Based on and subject to the foregoing, we are of the opinion that, when issued in accordance with the terms of the Plan and the options or other rights granted thereunder, the Registered Shares will be duly authorized, validly issued, fully paid and nonassessable by the Company.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus forming a part of the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Sullivan & Worcester LLP

SULLIVAN & WORCESTER LLP

![](tm268351d1_ex5-1img02.jpg)

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2020 Equity Incentive Plan of DarioHealth Corp. of our report dated March 10, 2025, with respect to the consolidated financial statements of DarioHealth Corp. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

---

| | |
|:---|:---|
|  | /s/ KOST FORER GABBAY & KASIERER |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tel-Aviv, Israel | KOST FORER GABBAY & KASIERER |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 19, 2026 | A Member of Ernst & Young Global |

---

## Exhibit 23.2

**Exhibit 23.2**

![](tm268351d1_ex23-2img01.jpg)

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of DarioHealth Corp. of our report dated March 19, 2026 relating to the financial statements, which appears in DarioHealth Corp.'s Annual Report on Form 10-K for the year ended December 31, 2025.

---

| | |
|:---|:---|
|  | ![](tm268351d1_ex23-2img02.jpg) |
| Tel Aviv, Israel | /s/ Kesselman & Kesselman |
| March 19, 2026 | Certified Public Accountants (Isr.) |
|  | A member firm of PricewaterhouseCoopers International Limited |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **DarioHealth Corp.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share | 457(a) | 1135000 | $9.15 | $10385250.00 | 0.0001381 | $1434.20 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $10385250.00  |  | $1434.20  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1434.20  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers an indeterminate number of additional securities which may be offered and issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions. Represents shares of common stock issuable upon stock options or other awards to be granted pursuant to the Company's Amended and Restated 2020 Equity Incentive Plan, as amended. The fee is based on the number of shares of common stock which may be issued under the plan this registration statement relates to and is estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low sales price of DarioHealth Corp.'s common stock as reported on the Nasdaq Capital Market on March 13, 2026.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---